C4 Therapeutics Financials

CCCC Stock  USD 4.38  0.13  3.06%   
Based on the key indicators related to C4 Therapeutics' liquidity, profitability, solvency, and operating efficiency, C4 Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, C4 Therapeutics' Current Deferred Revenue is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 2.6 M, whereas Total Assets are forecasted to decline to about 362.8 M. Key indicators impacting C4 Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.786.3412
Way Down
Pretty Stable
Investors should never underestimate C4 Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor C4 Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in C4 Therapeutics.

Net Income

(125.87 Million)

  
Understanding current and past C4 Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of C4 Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in C4 Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.

C4 Therapeutics Stock Summary

C4 Therapeutics competes with Shattuck Labs, Eliem Therapeutics, Prelude Therapeutics, Monte Rosa, and Foghorn Therapeutics. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS12529R1077
CUSIP12529R107
LocationMassachusetts; U.S.A
Business Address490 Arsenal Way,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.c4therapeutics.com
Phone617 231 0700
CurrencyUSD - US Dollar

C4 Therapeutics Key Financial Ratios

C4 Therapeutics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets118.3M400.1M506.8M430.8M376.5M362.8M
Other Current Liab6.7M8.5M12.3M15.1M15.4M11.2M
Other Liab72.7M53.6M24.4M16.9M15.2M14.4M
Net Tangible Assets(112.0M)280.8M389.6M289.2M332.6M168.9M
Net Debt(76.8M)(158.8M)(33.2M)57.4M(55.6M)(58.4M)
Retained Earnings(117.5M)(183.8M)(267.7M)(395.9M)(528.4M)(502.0M)
Accounts Payable5.4M5.7M4.5M1.2M1.4M2.6M
Cash90.5M181.7M76.1M29.8M126.6M99.2M
Net Receivables4.6M4.5M5.7M1.5M11.8M15.3M
Other Current Assets1.6M9.7M21.4M9.9M5.7M9.0M
Total Liab230.2M119.3M117.2M141.6M130.3M128.7M
Net Invested Capital(112.0M)290.8M400.4M300.7M246.1M191.8M
Total Current Assets96.8M381.0M325.7M287.6M271.2M272.4M
Net Working Capital63.1M337.2M274.4M243.0M228.4M228.4M
Short Term Debt880K2.1M2.7M11.7M10.4M5.2M

C4 Therapeutics Key Income Statement Accounts

201920202021202220232024 (projected)
Net Interest Income1.8M(836K)(1.8M)1.4M6.6M6.9M
Interest Income1.8M393K387K3.6M8.6M9.0M
Interest Expense2.2M1.2M2.1M2.2M1.4M1.7M
Total Revenue21.4M33.2M45.8M31.1M20.8M31.5M
Gross Profit(26.3M)(44.3M)42.9M23.5M(97.0M)(92.1M)
Operating Income(35.5M)(60.4M)(82.1M)(129.5M)(139.0M)(132.1M)
Ebit(35.5M)(65.7M)(81.7M)(131.9M)(129.8M)(123.3M)
Research Development48.1M78.4M94.7M117.8M117.7M89.0M
Ebitda(33.9M)(62.9M)(78.8M)(124.3M)(122.1M)(116.0M)
Income Before Tax(33.3M)(67.0M)(83.9M)(128.2M)(131.2M)(124.7M)
Net Income(34.1M)(66.3M)(86.0M)(126.5M)(132.5M)(125.9M)
Income Tax Expense804K(626K)2.1M(1.7M)1.3M1.3M

C4 Therapeutics Key Cash Accounts

201920202021202220232024 (projected)
Investments(1.6M)(190.5M)(188.1M)58.4M135.7M142.5M
Change In Cash54.2M91.2M(104.9M)(46.4M)97M101.9M
Free Cash Flow54.3M(67.9M)(88.2M)(111.4M)(108.5M)(103.1M)
Depreciation1.6M1.6M1.5M1.7M1.9M1.7M
Other Non Cash Items1.1M1.6M2.1M7.3M3.5M3.3M
Capital Expenditures1.3M650K1.3M5.5M1.7M2.4M
Net Income(34.1M)(66.3M)(83.9M)(128.2M)(132.5M)(125.9M)
End Period Cash Flow93.1M184.3M79.4M33.0M130.0M102.4M
Change To Netincome2.0M10.2M21.5M30.0M34.5M36.2M

CCCC Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across C4 Therapeutics competition to find correlations between indicators driving C4 Therapeutics's intrinsic value. More Info.
C4 Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, C4 Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.

C4 Therapeutics Systematic Risk

C4 Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. C4 Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on C4 Therapeutics correlated with the market. If Beta is less than 0 C4 Therapeutics generally moves in the opposite direction as compared to the market. If C4 Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one C4 Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of C4 Therapeutics is generally in the same direction as the market. If Beta > 1 C4 Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in C4 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various C4 Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of C4 Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.65)

At present, C4 Therapeutics' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

C4 Therapeutics November 25, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of C4 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of C4 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of C4 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing CCCC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build C4 Therapeutics's daily price indicators and compare them against related drivers.

Complementary Tools for CCCC Stock analysis

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios